The vaccine was approved in the U.S. in 2019 to prevent orthopoxvirus infections in high-risk adults.
The United States (US) Centers for Disease Control and Prevention (CDC) released recommendations on a smallpox vaccine on Friday from a panel of independent experts, limiting its usage to persons who work closely with viruses like monkeypox. At a time when monkeypox infections have spread across Europe, the U.S. , and beyond, Bavarian Nordic's Jynneos vaccine will be available for specific healthcare workers and laboratory personnel. In the U.S. , the vaccine was approved in 2019 to prevent smallpox and monkeypox in high-risk adults aged 18 and up. Officials from the CDC said earlier last week that certain doses of the Jynneos vaccine for people who have come into contact with confirmed monkeypox patients would be available soon.
Officials claimed there were more than 100 million doses of ACAM2000, an earlier smallpox vaccine developed by Emergent BioSolutions, which has significant side effects. Monkeypox is a mild viral infection that is widespread in areas of Africa, but a recent outbreak in countries where the virus is not normally disseminated has caused concern. There have been approximately 300 confirmed or suspected cases in up to 20 countries where the virus had not previously circulated. The World Health Organization (WHO) has urged governments to act quickly to stop the spread of monkeypox. The CDC announced on Friday that both ACAM2000 and Jynneos are available for the prevention of orthopoxvirus infections in at-risk people.